ArticleProtein science : a publication of the Protein Society2026
Role of the transmembrane domain in severe acute respiratory syndrome (SARS) coronavirus 2 spike for palmitoylation and membrane fusion.
Article in Protein science : a publication of the Protein Society, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Role of the transmembrane domain in severe acute respiratory syndrome (SARS) coronavirus 2 spike for palmitoylation and membrane fusion.Protein science : a publication of the Protein Society · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
Abstract
Palmitoylation is a reversible post-translational modification that enhances protein hydrophobicity and regulates cellular functions such as trafficking and signaling. In humans, this modification is catalyzed by 23 DHHC enzymes, but the mechanisms by which they recognize their substrates remain unclear. The severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein undergoes palmitoylation primarily by DHHC20 with subsequent modification by DHHC9 at 10 cytoplasmic tail (CT) cysteines, a modification crucial for membrane fusion and viral entry. Using AlphaFold2 modeling and site-directed mutagenesis, we identified three key components critical for efficient spike palmitoylation: (i) Lys1211 at the ectodomain-transmembrane domain (TMD) interface, likely facilitating electrostatic interactions with DHHC20's acidic residues; (ii) a stable trimeric TMD helix, where mutations at the trimer interface impair palmitoylation, in contrast to changes in outward-facing residues; and (iii) a conserved hydrophilic motif in the CT, located between acylated cysteine clusters, likely promoting optimal substrate positioning near DHHC20's catalytic site. Co-immunoprecipitation assays revealed that mutations in these residues disrupt spike-DHHC20 interactions, while leaving spike-DHHC9 binding unchanged, suggesting that they affect enzyme-substrate complex formation. Fusion assays revealed nuanced effects; while palmitoylation generally correlated positively with membrane fusion, certain exceptions highlighted the complex relationship between these processes. Mutations in the CT markedly reduce total spike palmitoylation but only modestly affect cell-cell fusion. Some substitutions in the TMD impair fusion with little change in overall acylation. Our findings elucidate the structural and biophysical determinants of spike palmitoylation and its distinct roles in membrane fusion, offering insights into SARS-CoV-2 pathogenesis and potential antiviral targets.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.